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Abstract Five distinct human somatostatin receptor subtypes 
have recently been cloned and characterized. Previous studies 
have suggested that these receptor subtypes might display 
coexistent localization, based on in situ hybridization or 
immunoblockage experiments. Here we provide evidence for 
coexistence of somatostatin receptor subtypes 2 and 5 in the 
human neuroblastoma cell line LA-N-2, using a combined 
approach with RT-PCR and receptor binding studies with 
somatostatin analogues. Somatostatin receptor subtypes simul-
taneously localized to a single cell might serve distinct functions 
in terms of targeting to different intraneuronal compartments or 
subtype specificity against so far unidentified somatostatin-
related peptides. 
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1. Introduction 
Somatostatin (SS) is a neuropeptide with a wide distribu-
tion in the central nervous system (CNS) and peripheral tis-
sues such as the pancreas and gastrointestinal tract [1,2]. It 
exerts various hormonal actions like inhibition of growth hor-
mone (GH), thyroid stimulating hormone (TSH), insulin and 
glucagon secretion [3]. Furthermore, this neuropeptide has 
been demonstrated to influence complex behavioral functions 
such as locomotor activity and cognition [4,5]. Thus hetero-
geneity of the SS receptor has for a long time been suggested 
and supported by experimental data such as the biphasic man-
ner of ligand displacement [6] and divergent functional effects 
of SS-immunoreactive forms [7]. The definitive evidence for 
multiple receptors was provided by the molecular cloning of 
five different receptor subtypes (for review [8]). 
We have recently identified a human neuroblastoma cell 
line with expression of a single SS transcript, the prohormonal 
form (proSSi_92), the processed form SS-28 as well as high-
affinity receptors with sensitivity to G-protein uncoupling [9]. 
The aim of the present study was to investigate which SS 
receptor subtypes were expressed in this cell line. Several 
authors have previously shown coexistent expression of SS 
receptor subtype transcripts and suggested simultaneous oc-
currence of multiple SS receptor subtypes in a single cell 
[10,11]. Here we provide evidence for multiple SS receptor 
subtypes in the clonal neuroblastoma cell line LA-N-2 using 
a combined approach with RT-PCR methodology and com-
petitive radioligand binding with subtype-specific analogues. 
"■Corresponding author. Fax: (46) (8) 746 5235. 
2. Materials and methods 
2.1. Cell culture 
The neuroblastoma cell line LA-N-2 was grown at 37°C in RPMI-
1640 culture medium (Gibco BRL, Life Technologies) supplemented 
with 10% fetal calf serum, L-glutamine 0.29 mg/ml, penicillin 100 IU/ 
ml and streptomycin 50 (xg/ml in humidified air containing 5% C02. 
The medium was changed every third day. Confluent cells (2xl05 
cells/cm2) were washed once in ice-cold phosphate-buffered saline 
(PBS, 137 mM NaCl, 10 mM Na2HP04, 1.6 mM NaH2P04, pH 
7.4) supplemented with 10 mM EDTA and harvested in ice-cold 
PBS buffer. The cell pellet used for RNA preparation and 
[125I]LTT-SS-28 receptor binding was obtained by centrifugation at 
1000 Xg for 5 min at 25°C. 
2.2. Human postmortem brain 
Brain tissue was obtained at autopsy from two female subjects at 64 
and 79 years of age (both with a postmortem delay of 5 h) without 
previous signs of neurological or psychiatric disorders (Huddinge 
Brain Bank). The left hemisphere was dissected into discrete regions 
and slowly frozen at —70°C, while the right hemisphere was fixed in 
10% buffered neutral formalin. Paraffin-embedded material was 
stained in various ways to exclude neuropathological changes at 
macroscopic or microscopic levels. Synaptosomal membrane prepara-
tion was prepared from tissue material that had been slowly thawed 
on ice and then homogenized in 10 volumes (w/v) of ice-cold 0.32 M 
sucrose using a glass-teflon homogenizer. Subsequent centrifugation 
steps were carried out in a similar way as for the neuroblastoma cells. 
2.3. RNA preparation and RT-PCR 
Total RNA (250 ug) was extracted [12] and treated with DNase I, 
amplification grade (5 U; Life Technologies) according to the manu-
facturer's instructions in the presence of RNasin (1 U/al; Promega) to 
eliminate remaining genomic DNA. The RNA extraction procedure 
was repeated once to remove possible remaining DNase. Single 
stranded cDNA was synthesized from total RNA (~30 ug) using 
oligo(dT)-primed and reverse-primed AMV reverse transcriptase (1 
U/ug total RNA; Promega). The cDNA was amplified with Taq 
DNA polymerase (1.5 U; Boehringer) in 50 ul reaction assays with 
cycles of 95°C for 1 min, 65°C for 1 min, 72°C for 1 min and a final 
period at 72°C for 10 min. The primers were designed with a similar 
GC content and checked for other sequences with similarity in the 
EMBL gene database (FASTA; Table 1). The primer pairs for the 
human SS gene were located in separate exons and in the intron to 
serve as a positive control as well as to reveal possible contamination 
with genomic DNA. Following 40 cycles the amplification reaction 
(15 ul) was electrophoretically separated on an 3.0% agarose gel. 
Genomic DNA was purified with a QIAamp tissue kit (Qiagen, Ger-
many). The amplified DNA bands were excised, purified with QIA-
quick (Qiagen, Germany) and further investigated by restriction en-
donuclease mapping. 
2.4. [125I]LTT-SS-28 receptor binding assay 
Pelleted cells (~108 cells) were dissolved in 5 ml ice-cold 50 mM 
Tris-HCl (pH 7.4), homogenized with a glass-teflon homogenizer and 
centrifuged at 700Xg for 10 min at 4°C. The supernatant was cen-
trifuged at 14000Xg for 30 min at 4°C and the pellet obtained re-
suspended in 1 ml 50 mM Tris buffer (pH 7.4) and frozen at —20°C 
until use in binding assays. Membrane suspensions were thawed and 
diluted in 5 ml ice-cold 50 mM HEPES-KOH buffer (pH 7.5). The 
mixture was centrifuged at 11000Xg for 30 min at 4°C and the pellet 
resuspended in fresh buffer to give a protein concentration of approxi-
0014-5793/97/S17.00 © 1997 Federation of European Biochemical Societies. All rights reserved. 
PII S00 14- 5793 (9 6)0144 1-X 
84 L. Nilsson, R. FolkessonlFEBS Letters 401 (1997) 83-88 
mately 1.5 ug/ul. The ligand, LTT-SS-28 (3 ug; Sigma), was iodinated 
with 125I (1 mCi, 556 mCi/ml; Amersham) using the chloramine-T (1 
ug) method in a total volume of 27 ul and separated on a 5 um Qg 
reversed-phase HPLC column (LKB, Stockholm) [17]. The column 
was eluted at room temperature at 0.5 ml/min with 10-40% CH3CN 
and 0.1% trifluoroacetic acid. Dilutions of peptides and radioactive 
ligand were made in the incubation buffer which consisted of 50 mM 
HEPES-KOH buffer (pH 7.5) containing 0.2 mg/ml bovine serum 
albumin (BSA), 5 mM MgCl2, 0.03 mg/ml bacitracin, 200 kIU/ml 
aprotinin and 0.02 |ig/ml PMSF. Binding assays were performed in 
precoated Eppendorf tubes (0.5 mg/ml BSA in redistilled water). 
Membrane preparation (~120 ug protein) and [125I]LTT-SS-28 
(1050 Ci/mmol) was incubated for 60 min at 30°C in the absence or 
presence of increasing concentrations of peptide analogues in a final 
volume of 200 ul. The incubation was terminated by centrifugation at 
13000Xg for 1 min, the supernatant was aspirated and the pellet 
washed with 1.25 ml ice-cold incubation buffer. Tissue-bound radio-
activity was determined following a second centrifugation and aspira-
tion. Non-specific binding was defined as binding in the presence of 
1 uM unlabeled SS-14. All assays were performed in triplicate. Protein 
determinations were measured by the method of Lowry et al. [18], The 
following peptides and analogues were used: Octreotide (Sandostatin, 
Sandoz) and SS-14 (Peninsula). The CGPIII analogue was synthesized 
and checked with mass spectroscopy by Dr. Gunnar Holmberg, Im-
munology Department, Uppsala, Sweden. DC23-60 was kindly pro-
vided by Dr. W. Murphy and Dr. D. Coy, Tulane University, New 
Orleans, LA, USA. 
3. Results 
A RT-PCR methodology was initially developed to screen 
for presence of SS receptor subtype transcripts due to the high 
sensitivity of this technique and limited need of mRNA. The 
human SS mRNA was used as a positive control transcript, 
since gene expression has been previously demonstrated in the 
LA-N-2 cell line with Northern blot [9]. The transcript was 
amplified with primers located in separate exons at various 
annealing temperatures to evaluate the stringency of the 
PCR conditions. A single band was obtained at annealing 
temperatures between 55°C and 70°C, although the yield 
was lower at 70°C (Fig. 1A). Control experiments using 
exon primers of the SS gene revealed a single band ( ~ 1100 
bp) in the genomic DNA and one band ( ~ 200-250 bp) in the 
cDNA preparation (Fig. IB), while the intron primers pro-
duced a single band ( ~ 250-300 bp) in the genomic DNA 
from the cell line as expected (Fig. 1C). In contrast, no signs 
of contaminating genomic DNA were evident either in the 
cDNA preparation, the RNA preparation not subjected to 
reverse transcription or in the reagents supplied with the re-
verse transcriptase kit (Fig. 1B,C). Primers for the different SS 
receptor subtypes were used at an annealing temperature of 
65°C. The subtypes SSTR2 and SSTR5 were found to be 
expressed in the cell line, while the SSTR1, SSTR3 and 
SSTR4 transcripts were not detected. No bands were present 
when the cDNA was replaced by RNA preparation not sub-
jected to reverse transcription in the PCR reactions (Fig. 
1D,E). The genuineness of the amplified DNA bands was 
verified by the presence of two nondegenerated hexamer re-
striction endonuclease motifs. 
In order to investigate whether these subtypes were trans-
lated into receptor proteins competitive binding experiments 
with [125I]LTT-SS-28 as ligand and various subtype-specific 
peptide analogues were used [17]. The iodinated ligand, 
[125I]LTT-SS-28, was checked by saturation binding experi-
ments. Specific binding to membrane preparations from hu-
man medial frontal cortex was found to consist of a single 
population of high-affinity binding sites (Bmax = 19.46 ± 1.94 
fmol/mg protein; K¿ = 0.46 ± 0.08 nM; Hill coefficient = 
0.97±0.12; « = 3; Fig. 2A,B). The assay conditions were the 
same as those of Srikant and Patel except that a higher con-
centration of bacitracin was used in previous experiments 
(0.03 mg/ml instead of 0.02 |ig/ml; [9]). The higher concentra-
tion was used since initial experiments showed that the specific 
binding to cellular membrane preparations was unstable at 
equilibrium using low concentrations of bacitracin. The 
high-affinity interaction between the ligand and the binding 
site was unaffected by this change as determined by associa-
tion kinetics and displacement studies (data not shown). 
The presence of SS receptor encoded proteins in synapto-
somal membrane preparations was investigated using compe-
titive radioligand binding (Fig. 3A-C; Table 2). The SS ana-
logues SMS201-995 (selective for SSTR2, SSTR3 and SSTR5) 
and DC23-60 (selective for SSTR2 and SSTR5) as well as 
CGPIII (selective for SSTR5) were used together with the 
nonselective ligand SS-14. The SS analogue CGPIII displayed 
a biphasic manner of ligand displacement against synaptoso-
mal membrane preparations from the neuroblastoma cell line 
LA-N-2. The competitive binding curve fitted significantly 
better to a two-site model compared to a one-site model sug-
gesting two classes of receptor subtypes (^ 2,6 -5.35, P — 0.046, 
Tatest). The inhibition constants (p-K¡) were 10.3 ±0.9 and 
5.8 ± 0.2 (mean ± S.E.M.) for the high-affinity and low-affinity 
Table 1 
Primers used in the study 
Gene Primer (forward/reverse) Codon Size (bp) 
SSTR1 
[13] 
SSTR2 
[13] 
SSTR3 
[14] 
SSTR4 
[15] 
SSTR5 
[15] 
SOM-EXON 
SOM-INTRON 
[16] 
5'-TGCTGAGCAGGTCGACGCCA-3' 
5'-CTCTAGAGCGCGGTGGCGTA-3' 
5'-CCTCTAGAACCTGAGTGGGC-3' 
5' -G AGGAGG ATCCTCTGGGTCT-3' 
5'-ATCGTCGACGTGGTGTGCCC-3' 
5' -CCC ACAGTGGGATCCTGGTC-3' 
5' -GGTCGTGGTCG ACTTTGTGC-3' 
5'-AGTAGTCCAGGGGATCCTCC-3' 
5'-CAACATCGTCGACCTGGCCG-3' 
5' -TGTCTGGACGCGGATCCGTG-3' 
5'-GCTCCCTCGGATCCCAGACT-3' 
5' -TTGCGTTCCCGGGGTGCCAT-3' 
5' -CCCT AAGCCTTGCTCCTGCC-3' 
5'-CTTCCCAGGGTCAGCACCAG-3' 
987-1006 
1159-1178 
792-811 
1146-1165 
929-948 
1106-1125 
839-858 
1070-1089 
851-870 
1046-1065 
1303-1322 
2393-2412 
1410-1429 
1668-1687 
192 
374 
196 
250 
215 
233/1110 
278 
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binding sites. The fraction of high-affinity binding sites repre-
sented 15 ±5% (mean±S.E.M.) of total binding. Human 
postmortem pituitary tissue showed a one-site displacement 
curve (pÄj = 8.8±0.3) representing 60 ±6% of total binding, 
while a single low-affinity site was found in the cerebral cortex 
(pK¡ = 6.1 ±0.1). Competitive binding curves by the DC23-60 
ligand fitted to a one-site model with similar inhibition con-
stants for the LA-N-2 cell line (p£¡ = 8.8 ± 0.1, n = 4) as well as 
the pituitary (pK-, = 8.5 ±0.2, n = J) and the cerebral cortex 
(pK¡ = 8.4 ± 0.1, n = 4). The fraction of total binding displaced 
represented 94 ± 3%, 59 ± 3% and 79 ± 2% respectively. The SS 
analogues SMS201-995 also fitted to a one-site model for the 
LA-N-2 cell line (pAT¡ = 9.7±0.1, n = 4), the pituitary (p£¡ = 
8.6 ±0.3, M = 4) and the cerebral cortex (pA^ = 9.2 ±0.1, 
n = 3). The fraction of total binding displaced represented 
88 ±4%, 66 ±6% and 89 ± 3 % respectively. The SS-14 ligand 
which binds to all SS receptor subtypes with comparable af-
finity produced monophasic manner of ligand displacement in 
the neuroblastoma cell line (pK¡ =9.5 ±0.1, n = 3), the pitui-
tary (pKi = 8.9 ± 0.2, n = 3) as well as the cerebral cortex 
(pK¡ = 9.5 ± 0.1, n = 3) as expected. 
4. Discussion 
The present study demonstrates expression of multiple SS 
receptor transcripts (SSTR2 and SSTR5) in the human neu-
roblastoma cell line LA-N-2. The receptor binding data sug-
gest that both of these transcript are translated into receptor 
proteins. To our knowledge this is the first report where ex-
perimental evidence for coexistent SS receptors has been pro-
vided by detection of receptor subtype transcripts as well as 
radioligand binding studies. Furthermore this is one of few 
studies presenting experimental data on which SS receptor 
subtypes are present at high densities in human cerebral cor-
tex and pituitary. 
Four of the SS receptor genes are unspliced, while the 
SSTR2 gene has an intron generating the SSTR2A and 
SSTR2B transcripts [20]. Thus we were unable to locate our 
primers in different exons, but used primer pairs of the human 
Fig. 1. PCR amplification of cDNA from the human neuroblastoma 
cell line LA-N-2. Amplification reactions (15 |xl) were electrophoreti-
cally separated on a 3.0% agarose gel. The stringency of primer an-
nealing was evaluated using the somatostatin transcript as a positive 
control (lanes 1-4: 55°C, 60°C, 65°C and 70°C: A). Absence of 
genomic DNA was demonstrated in control experiments with pri-
mers located in separate exons (B) as well as the intron (C) (lanes 
1-5: genomic DNA, total RNA, cDNA, mixture of RT reagents 
and H2O). Various primer pairs were used to reveal expression of 
somatostatin receptor transcripts in total RNA preparation assayed 
in the presence (+) or absence (—) of reverse transcriptase (D and 
E). 
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Fig. 2. [125I]LTT-SS28 binding to synaptosomal membrane prepara-
tions of human medial frontal cortex with increasing concentration 
of ligand. Total (•), specific (■) and non-specific (o) binding were 
measured as described in Section 2 (A). Scatchard transformation of 
specific [125I]LTT-SS28 binding data (B). Each point represents the 
mean of binding data obtained from three separate experiments. 
SS gene located in separate exons as well as the intron to 
reveal possible contamination with genomic DNA. The inclu-
sion of a RT-PCR adapted RNase-free DNase as well as 
repeated RNA extraction was found necessary to eliminate 
trace amounts of genomic DNA as well as DNase with re-
maining stability of mRNA and nascent cDNA. The PCR-
amplified bands were of expected size on the agarose gel and 
the authenticity of both receptor transcripts was verified by 
two restriction endonucleases. 
A number of SS analogues with partial subtype specificity 
have been designed and pharmacologically characterized 
[21,22]. Recently several of these SS analogues were screened 
for their subtype selectivity against all five human receptor 
subtypes under identical experimental conditions [17]. We 
have adapted these assay conditions in our experiments, since 
the LA-N-2 cell line is of human origin. The ligand, [125I]LTT-
SS-28, displayed expected binding characteristics when tested 
in saturation binding experiments against human cerebral cor-
tical tissue [23,24]. 
In the current experiments only those SS analogues with 
pronounced selectivity for a particular receptor subtype/sub-
types were used. At low concentrations the cyclic ligand 
CGPIII partially displaced [125I]LTT-SS-28 binding to the 
neuroblastoma cell line suggesting the presence of SSTR5 re-
ceptor protein. The DC23-60 ligand, with high affinity for 
SSTR2 and SSTR5 subtypes, displayed an almost complete 
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displacement of [125I]LTT-SS-28 binding to the neuroblasto-
ma cell line. Thus the SSTR2 receptor subtype appears to be 
the predominant one in the neuroblastoma cell line LA-N-2, 
with low densities of the SSTR5 receptor subtype. The prom-
inence of the SSTR2 subtype in neuroblastoma tumors is in 
agreement with other studies [25,26]. Interestingly both the 
SSTR2 and SSTR5 subtypes have been demonstrated to in-
hibit cell proliferation, although by distinct intracellular 
mechanisms [27]. 
The SSTR5-selective analogue, CGPIII, displaced 
[125I]LTT-SS-28 binding to pituitary tissue membranes with 
high affinity suggesting that this receptor subtype is frequent 
in the pituitary. In contrast the density of the SSTR2 receptor 
subtype seemed to be negligible, since low concentrations of 
DC23-60 had no additional effect on binding displacement. 
The SMS201-995 ligand displaced [125I]LTT-SS-28 binding 
to a slightly higher degree in human pituitary membranes 
suggesting low densities of the SSTR3 receptor. Thus the 
SSTR5 subtype and an additional receptor subtype are pre-
dominant in the human pituitary. The SSTR5 subtype is the 
only subtype which preferentially binds SS-28 [28]. Interest-
ingly others have demonstrated a binding selectivity for SS-28 
as compared to SS-14 in pituitary membranes [29], as well as 
increased potency for inhibition of GH and TSH secretion 
[30,31]. However, our findings of low SSTR2 receptor density 
are rather surprising since the SSTR2 subtype has been con-
sidered crucial for hypothalamic-pituitary functions [8,21,22]. 
It should, however, be considered that the intrinsic activity for 
most of the SS analogues has been less well studied and that 
many SS analogues simultaneously display high affinity for 
SSTR2 and SSTR5 [17]. Furthermore, species differences 
might puzzle studies since the amino acid residues involved 
in receptor interaction with artificial ligands are likely less 
evolutionarily conserved [32]. 
In the human medial frontal cerebral cortex the density of 
the SSTR5 subtype appeared to be low, since the CGPIII 
ligand was unable to displace [125I]LTT-SS-28 binding at 
low concentrations. This finding is supported by other studies 
showing low levels of the SSTR5 mRNA in the cerebral cor-
tex [28]. The DC23-60 ligand displaced most of the [125I]LTT-
SS-28 binding with high affinity in the cerebral cortex. We 
conclude that the SSTR2 subtype is the major SS receptor 
subtype in the human cerebral cortex with low concentrations 
of SSTR3, since the SMS201-995 ligand additionally displaced 
[125I]LTT-SS-28 binding to a slight degree. This finding is also 
supported by others showing a predominance of SSTR2 in the 
cerebral cortex of monkey [33]. Thus SSTR2-selective ana-
logues, particularly of nonpeptidergic character, appear to 
be of interest in order to evaluate possible influence of SS 
on higher cognitive functions [5,34]. 
The affinities found for SS-14 and the high-affinity interac-
tion for the SS analogues DC23-60 and SMS201-995 closely 
resemble those presented by Patel and Srikant [17]. The in-
hibition constant for high-affinity binding of the CGPIII ana-
logue to human pituitary membranes is similar to that of 
SSTR5, while the low-affinity binding to receptor subtypes 
SSTR2, SSTR3 and SSTR4 was not exactly determined [17]. 
The only discrepancy was the affinity of the CGPIII analogue 
for neuroblastoma membranes which was higher than found 
following transient transfection of SSTR5 into CHO-K1 cells 
[17]. We suggest that this difference might be due either to 
inability to accurately determine the inhibition constant since 
the binding density was relatively low or to cell type-specific 
differences in post-translational modification of the SSTR5 
receptor subtype. We are aware that cell type-specific post-
translational modification in general might puzzle the binding 
data, thus the optimal control would have been transfected 
LA-N-2 cell cultures run in parallel with native cell cultures 
[35]. However, these differences probably exert a minor influ-
ence on the radioligand binding studies since the ligands chos-
en differ in their affinity for the receptor subtypes by several 
orders of magnitude. 
The purpose for neuronal coexistence of neuropeptide re-
ceptor subtypes might seem elusive since SS-14 displays al-
most identical affinity for all of the human SS receptor sub-
types, although the fifth SS receptor subtype preferentially 
binds SS-28 [28]. However, intracellular targeting mechanisms 
could regulate the trafficking of receptor subtypes differen-
tially resulting in distinct cellular localization. Thereby the 
SS receptor subtypes could fulfill separate aims of SS signaling 
in terms of both compartmentalization and signal transduc-
tion. An alternative theory could be that other yet undiscov-
ered neuropeptides display high affinity for certain SS receptor 
subtypes as has been shown for the tachykinin family of neu-
ropeptides [36]. Recently a brain-derived cDNA clone with a 
high degree of structural similarity to the preproSS gene at the 
carboxy-terminus was found [37]. The putative neuropeptide 
derived from the prohormone, termed cortistatin-14, exerted 
pharmacological actions via SS receptors. Interestingly the 
electrophysiological effects differed from those of SS-14. An 
appealing hypothesis is that cortistatin is a SS-related peptide 
which acts via certain SS receptor subtypes and perhaps even 
via some of the phylogenetically related opioid receptor sub-
types [38]. The mechanisms and functional consequences by 
which SS-immunoreactive and putative SS-related peptides 
mediate signaling via coexistent SS receptors remain to be 
established. 
Acknowledgements: We thank Prof. Bengt Winblad for access to hu-
man postmortem brain tissue from the Huddinge Brain Bank; Dr. 
Table 2 
Inhibition constants (p-K¡) for SS-14 and SS analogues 
LA-N-2 cell line 
Medial frontal cortex 
Pituitary 
SS-14 
9.5 ±0.1 (3) 
9.5 ±0.1 (3) 
8.9 ±0.2 (3) 
to LA-N-2 cell line and human 
SMS201-995 
9.7 ±0.1 (4) 
9.2 ±0.1 (3) 
8.6 ±0.3 (4) 
postmortem brain material 
DC23-60 
8.8 ±0.1 (4) 
8.4 ±0.1 (4) 
8.5 ±0.2 (3) 
CGPIII 
10.3 ±0.9 (5) 
5.8 ±0.2 (5) 
6.1 ±0.1 (3) 
8.8 ±0.3 (4) 
Results are the mean±S.E.M. Numbers in parentheses denote numbers of separate experiments. 
Binding data were fitted to one-site and two-site models and IC5o values determined by nonlinear regression analysis using the GraphPad Prism 2.0 
software (GraphPad, San Diego, CA). Values of the inhibition constants (pK¡, — logK¡) were estimated from competitive binding using the equation 
KY =IC5o/(l+L/Äd) where L is the concentration of the radioligand [19]. 
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Fig. 3. Competitive inhibition of [125I]LTT-SS28 binding to mem-
brane preparations from the neuroblastoma cell line LA-N-2 (A), 
the human medial frontal cerebral cortex (B) and human pituitary 
(C). SS14 (■) as well as the SS analogues (SMS201-995 (D), CGPIII 
(•) and D23-60 (o)) with varying subtype selectivity were used as 
displacers. Results are the mean ± S.E.M. of 3-5 separate experi-
ments. Total binding and non-specific binding was 4547 ±331 and 
1593 ±69 cpm (human medial frontal cortex), 1509 ±155 and 
647 ±116 cpm (human pituitary), 1126 ±110 and 673 ±67 cpm (the 
LA-N-2 cell line). 
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